Mylan NV struck a licensing agreement with Revance Therapeutics Inc. to develop a biosimilar of Allergan Plc’s blockbuster Botox wrinkle treatment.
LabCorp, a leading global life sciences company, announced that its Covance Drug Development business entered into a strategic technology agreement with GlaxoSmithKline plc (GSK).
A Georgia pediatric cardiologist pleaded guilty to wrongfully disclosing info about his patients to an Aegerion sales rep seeking to identify potential new users of an expensive cholesterol drug.
The U.S. Food and Drug Administration approved ZTlido, Sorrento Therapeutics Inc.’s non-opioid painkiller patch for nerve pain related to shingles.
A federal judge dismissed a lawsuit claiming that Coca-Cola Co.’s advertising for Diet Coke misleads people into thinking that consuming the soft drink assists in weight loss, and that it actually causes weight gain.
Viela Bio, based in Gaithersburg, Md., spun out of AstraZeneca Pharmaceuticals’ MedImmune with a Series A financing of up to $250 million.
Gene-editing company Inscripta will be able to expand its research capabilities and increase hiring after the company closed a Series C funding round of $55.5 million.
The European Medicines Agency is following in the footsteps of the U.S. Food and Drug Administration with plans to help pharma companies win approval for novel Alzheimer’s drugs.
Valeant Announces Licensing Agreement With Kaken Pharmaceutical Co., Ltd. To Develop And Commercialize New Chemical Entity For Psoriasis
Valeant Pharmaceuticals International Inc. announced that its subsidiary entered into an exclusive license agreement with Kaken Pharmaceutical Co. Ltd. to develop and commercialize products containing a new chemical entity, KP-470, which is an investigational compound for the topical treatment of psoriasis.
U.S. health regulators rejected Celgene Corp.’s application seeking approval of a key multiple sclerosis drug due to insufficient data, the company said.
Martin Shkreli will be responsible for $10.4 million in financial losses when he faces sentencing for defrauding hedge fund investors on March 9, 2018.
French company DBV Technologies said its Viaskin Milk product yielded successful results in a Phase II trial for patients suffering from IgE-mediated cow’s milk protein allergy.
Roche said the European Commission approved the Swiss Group’s drug Hemlibra for people with hemophilia A who have developed resistance to standard treatments.
Aldeyra signed a collaboration research deal with Johnson & Johnson’s Janssen Research & Development to develop drugs that sequester pro-inflammatory aldehyde mediators.
A coalition of 20 U.S. states sued the federal government over Obamacare, claiming the law was no longer constitutional.
Amgen today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending a label variation for Neulasta (pegfilgrastim) to include the Neulasta Onpro Kit.
Adscend Media will be hosting a webinar designed to help advertisers combat ad fraud. Titled, “Fighting Back Against Ad Fraud,” the hour-long webinar will provide strategies for desktop and mobile advertisers to minimize invalid traffic, using historical data from the Adscend platform. The free event also features a question and answer session with Adscend Media CEO Fehzan Ali, as well details on the company’s pioneering Total Fraud Defense technology.
With the 2018 theme #PressForProgress, a Panel of HBA leaders was assembled to share practical examples of how they have leveraged their HBA experience — what they have learned and the relationships they have developed — to move the needle in their own careers and enhance their organization’s performance.
Dr. Henry Li, a respected expert in preclinical pharmacology, will present a webinar showing data derived from CrownBio’s large-scale immunotherapy screening platform, MuScreen.
U.S. regulators approved expanded use of Eli Lilly and Co.’s Verzenio breast cancer drug as an initial treatment for certain women with advanced or metastatic disease.